NASDAQ:ALEC Alector (ALEC) Stock Price, News & Analysis $6.49 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.34▼$6.6350-Day Range$4.19▼$6.5852-Week Range$3.66▼$9.06Volume408,850 shsAverage Volume669,558 shsMarket Capitalization$625.57 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Alector alerts: Email Address Alector MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside115.7% Upside$14.00 Price TargetShort InterestBearish6.50% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.80Based on 5 Articles This WeekInsider TradingSelling Shares$192,456 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.93) to ($1.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.04 out of 5 starsMedical Sector205th out of 936 stocksBiological Products, Except Diagnostic Industry25th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingAlector has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageAlector has only been the subject of 2 research reports in the past 90 days.Read more about Alector's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.50% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Alector has recently increased by 14.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlector has received a 70.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for diseases with neurocognitive impairment" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Alector is -0.92. Previous Next 3.2 News and Social Media Coverage News SentimentAlector has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Alector this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for ALEC on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows2 people have added Alector to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $192,456.00 in company stock.Percentage Held by InsidersOnly 9.10% of the stock of Alector is held by insiders.Percentage Held by Institutions85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alector's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alector are expected to grow in the coming year, from ($1.93) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alector's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Alector Stock (NASDAQ:ALEC)Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More ALEC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALEC Stock News HeadlinesJuly 23, 2024 | globenewswire.comAlector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024July 22, 2024 | americanbankingnews.comAlector, Inc. (NASDAQ:ALEC) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 12, 2024 | seekingalpha.comAlector: Brain Science Play With High Expenses And Few CatalystsJune 10, 2024 | globenewswire.comAlector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology PlatformMay 19, 2024 | finance.yahoo.comHere's Why We're Watching Alector's (NASDAQ:ALEC) Cash Burn SituationMay 9, 2024 | globenewswire.comAlector to Participate in Upcoming Healthcare ConferencesMay 9, 2024 | investorplace.comALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024July 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 8, 2024 | sfgate.comAlector: Q1 Earnings SnapshotApril 30, 2024 | finance.yahoo.comAlector, Inc. (ALEC)April 27, 2024 | nasdaq.comAlector, Inc. Common Stock (ALEC)April 19, 2024 | msn.comAlzheimer's Agitation Relapse Delayed With Dextromethorphan-BupropionApril 11, 2024 | finance.yahoo.comThe past five years for Alector (NASDAQ:ALEC) investors has not been profitableMarch 17, 2024 | finance.yahoo.comALEC Jan 2025 7.500 callMarch 16, 2024 | finance.yahoo.comALEC Oct 2024 7.500 putMarch 7, 2024 | markets.businessinsider.comAlector’s Clinical Progress and Financial Health Anchor Buy RecommendationMarch 1, 2024 | finance.yahoo.comThe Alector, Inc. (NASDAQ:ALEC) Full-Year Results Are Out And Analysts Have Published New ForecastsSee More Headlines Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALEC CUSIPN/A CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees270Year Founded2013Price Target and Rating Average Stock Price Target$14.00 High Stock Price Target$35.00 Low Stock Price Target$4.00 Potential Upside/Downside+115.7%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130,390,000.00 Net Margins-125.11% Pretax Margin-120.63% Return on Equity-71.80% Return on Assets-18.28% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.53 Sales & Book Value Annual Sales$97.06 million Price / Sales6.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book4.60Miscellaneous Outstanding Shares96,390,000Free Float87,614,000Market Cap$625.57 million OptionableOptionable Beta0.73 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Arnon Rosenthal Ph.D. (Age 68)Co-Founder, CEO & Director Comp: $1.02MDr. Sara Kenkare-Mitra Ph.D. (Age 56)President and Head of Research & Development Comp: $1.19MDr. Marc Grasso M.D. (Age 50)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $738.05kDr. Gary Romano M.D. (Age 62)Ph.D., Chief Medical Officer Comp: $602.98kMr. Peter Heutink Ph.D.Chief Scientific OfficerKatie HoganSenior Director of Corporate Communication & Investor RelationsMs. Danielle Pasqualone J.D.Ph.D., General CounselMs. Clare Hunt M.B.A.Chief People OfficerMs. Kristina Cutter M.P.H.Chief Regulatory, Pharmacovigilance, & Quality Assurance OfficerMs. Virginia DeJesus-Rueff M.B.A.Chief of Staff & Head of StrategyMore ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSNantKwestNASDAQ:NKREGENXBIONASDAQ:RGNXC4 TherapeuticsNASDAQ:CCCCBlack Diamond TherapeuticsNASDAQ:BDTXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 49,625 shares on 7/26/2024Ownership: 0.290%Baillie Gifford & Co.Sold 62,387 shares on 7/25/2024Ownership: 0.270%Gladius Capital Management LPBought 6,402 shares on 7/19/2024Ownership: 0.007%SG Americas Securities LLCBought 64,183 shares on 7/12/2024Ownership: 0.067%Arnon RosenthalSold 25,135 sharesTotal: $120,648.00 ($4.80/share)View All Insider TransactionsView All Institutional Transactions ALEC Stock Analysis - Frequently Asked Questions How have ALEC shares performed this year? Alector's stock was trading at $7.98 on January 1st, 2024. Since then, ALEC stock has decreased by 18.7% and is now trading at $6.49. View the best growth stocks for 2024 here. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) announced its earnings results on Wednesday, May, 8th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.10. The firm had revenue of $15.89 million for the quarter, compared to analyst estimates of $14.63 million. Alector had a negative net margin of 125.11% and a negative trailing twelve-month return on equity of 71.80%. What is Arnon Rosenthal's approval rating as Alector's CEO? 4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Does Alector have any subsidiaries? The following companies are subsidiaries of Alector: Alector LLC. When did Alector IPO? Alector (ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO. Who are Alector's major shareholders? Alector's top institutional shareholders include Bank of New York Mellon Corp (0.29%), Baillie Gifford & Co. (0.27%), SG Americas Securities LLC (0.07%) and Gladius Capital Management LP (0.01%). Insiders that own company stock include Polaris Venture Management Co, Arnon Rosenthal, Robert King, Gary Romano, Sara Kenkare-Mitra, Marc Grasso, Shehnaaz Suliman, Richard H Scheller and Robert Paul. View institutional ownership trends. How do I buy shares of Alector? Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO) and QUALCOMM (QCOM). This page (NASDAQ:ALEC) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
